PBAC's latest decision on Tazarotene: Not recommended (2007). Considered for chronic stable plaque type psoriasis vulgaris.
PBAC outcome
Not recommended
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
patients (or lesions/sides) treated with tazarotene compared with calcipotriol
Therapy area
Dermatology
Line of therapy
First-line
Evidence base
RCT | Single-arm
Primary endpoint
Treatment success, mean change from baseline in erythema, pruritus, plaque elevation and scaling
Key trials
Guenther (2000), Schiener (2000), Tzung (2005)
Comparator
calcipotriol
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach used; economic analysis not considered valid by Committee due to uncertain comparative efficacy
Why PBAC said no
Reasons cited in the latest PSD: Uncertain clinical benefit in comparison with calcipotriol, formulation mismatch (key trials used gel not cream), insufficient evidence of non-inferiority, potentially higher adverse event incidence than comparator, sparse adverse event data, wide confidence intervals in comparative trial, unbalanced corticosteroid use in comparator arm